M+QuickMedCalc
Educational reference only. Not a diagnostic tool. See full disclaimer.
PulmonologyBODE Index

BODE Index Calculator for COPD

Calculate the original Celli 2004 BODE Index for clinically stable, established COPD from BMI, post-bronchodilator FEV₁ % predicted, mMRC dyspnea, and 6-minute walk distance.

Content updated: View sources

QuickMedCalc is developed and maintained by an independent developer. Medical content is not independently reviewed by a physician.

Formula and medical content are based on the references listed on this page. See sources, About, and Sources and Review Process.

Original Celli 2004 BODE assessment

Enter the four direct source measurements. No missing value is scored as zero.

The source-compatible calculation is for established COPD assessed while clinically stable. BODE does not diagnose COPD and is not an acute-exacerbation score. [1]

Enter the measured/calculated BMI directly. BMI ≤21 adds 1 point; BMI >21 adds 0. The calculator does not retrieve body-size data from another page. [1]

Use the post-bronchodilator percent predicted reported with the spirometry interpretation—not raw FEV₁ litres, FEV₁/FVC, a pre-bronchodilator value, or a GOLD stage. The reporting reference equation determines % predicted; this calculator does not invent or change it. [1]

Choose the full modified MRC description; do not substitute the differently numbered original MRC 1–5 scale. [1]

Enter a valid recorded whole-metre 6MWT result. The original BODE development used the best of two tests at least 30 minutes apart; current ERS/ATS standards also document a learning effect and standardized methodology. Missing, inability to test, an estimate, steps, or treadmill distance is not 0 m. [1, 2, 3]

Select the stable-COPD assessment context and complete all four source measurements to display the BODE total, original quartile, and calculation audit.

About

This BODE Index Calculator reproduces the original Celli 2004 score for established COPD assessed in a clinically stable setting. BODE stands for body mass index, airflow obstruction, dyspnea, and exercise capacity. [1]

It requires BMI, post-bronchodilator FEV₁ as percent of predicted, the full mMRC 0–4 dyspnea grade, and a valid recorded 6-minute walk distance. It does not diagnose COPD, estimate an individual life expectancy, or replace the source measurement protocols.

Formula

Original Celli 2004 BODE = BMI points + post-bronchodilator FEV₁ % predicted points + mMRC points + 6MWD points
Total = 0–10; original quartiles: 0–2, 3–4, 5–6, and 7–10
Formula identity: bode-celli-2004

Interpretation

Component0 points1 point2 points3 points
BMI, kg/m²>21≤21
Post-BD FEV₁, % predicted≥6550 to <6536 to <50<36
mMRC grade0–1234
6MWD, m≥350250–349150–2490–149

The original quartiles are 0–2 (Quartile 1), 3–4 (Quartile 2), 5–6 (Quartile 3), and 7–10 (Quartile 4). These are source quartiles, not “mild,” “moderate,” “severe,” or patient-specific probability labels. [1]

Current guideline limitation

NICE NG115 says not to use a multidimensional index such as BODE to assess prognosis in people with stable COPD. It recommends considering multiple individual prognostic factors instead. BODE remains a historically validated index, but this page does not describe it as the current routine prognostic standard. [1, 4]

Historical cohort context, not an individual survival estimate

The original study evaluated 207 people during model development and prospectively validated the index in 625. In the validation cohort, 162 died; each one-point increase was associated with an all-cause-death hazard ratio of 1.34 (95% CI 1.26–1.42), and the C statistic was 0.74 for BODE versus 0.65 for FEV₁ alone. These are study-level results, not personal probabilities. [1]

A score of 8 is 8/10 and belongs to original Quartile 4 (scores 7–10). That quartile had 80% mortality at 52 months in the original validation cohort. QuickMedCalc does not convert this historical cohort observation—or secondary websites’ approximate quartile survival figures—into “your survival,” life expectancy, or a large survival-percentage result. [1]

Why transplant sources still mention BODE

GOLD 2026 and ISHLT 2021 still include BODE among multiple factors considered in selected advanced-COPD lung-transplant pathways. Scores 5–6 appear in referral context and scores 7–10 in listing context alongside disease progression, FEV₁, exacerbations, gas exchange, pulmonary hypertension, treatment status, quality of life, and other factors. A BODE score alone does not trigger referral or listing here. [5, 6]

ISHLT also describes imperfect calibration: in 4,377 OPTN/UNOS COPD transplant candidates, Quartile 4 median survival was 59 months versus 37 months in the original BODE cohort, and the original model overestimated mortality in this selected population. This is why transplant context cannot be reduced to one automated BODE action. [6]

Original BODE versus modified models

Modified or updated BODE, mBODE, e-BODE, BODEx, i-BODE, and ADO are distinct research models or variants that change or add inputs. They are not interchangeable with original Celli 2004 BODE and are not calculated on this page. [7]

References

  1. Celli BR, Cote CG, Marin JM, et al. The Body-Mass Index, Airflow Obstruction, Dyspnea, and Exercise Capacity Index in Chronic Obstructive Pulmonary Disease. N Engl J Med. 2004;350(10):1005–1012. PMID 14999112. DOI 10.1056/NEJMoa021322.
  2. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166(1):111–117. PMID 12091180. DOI 10.1164/ajrccm.166.1.at1102.
  3. Holland AE, Spruit MA, Troosters T, et al. An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease. Eur Respir J. 2014;44(6):1428–1446. PMID 25359355. DOI 10.1183/09031936.00150314.
  4. National Institute for Health and Care Excellence. Chronic obstructive pulmonary disease in over 16s: diagnosis and management (NG115). Recommendation 1.1.24: assessing severity and using prognostic factors. Published 2018; last updated 2019.
  5. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for Prevention, Diagnosis and Management of COPD: 2026 Report. Lung-transplantation section.
  6. Leard LE, Holm AM, Valapour M, et al. Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2021;40(11):1349–1379. PMID 34419372. PMCID PMC8979471. DOI 10.1016/j.healun.2021.07.005.
  7. Puhan MA, Garcia-Aymerich J, Frey M, et al. Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index. Lancet. 2009;374(9691):704–711. PMID 19716962. DOI 10.1016/S0140-6736(09)61301-5.

FAQ

Related Calculators

Disclaimer

Educational and informational reference only. Not intended to replace professional medical advice, diagnosis, treatment, or independent verification.